Antibodies are Y-shaped proteins produced in the immune system to thwart the attack of bacteria and viruses. They target these harmful agents by identifying the antigens. It is also known as immunoglobulin (Ig). These antibodies are manufactured by biopharmaceutical and biotechnology companies using the cell gene expression system. Monoclonal (mAbs) and polyclonal (pAbs) antibodies are artificial immune cells created by these companies to target specific cells for better treatment of cancer and blood disorders. The increasing demand of these antibodies is driving the antibody production market.
Technological advances in the market have led to the development of antibody-drug conjugates (ADCs). These antibodies are able to target cancer cells without affecting any healthy cells. This drug delivers a cytotoxic agent using cell surface markers. The U.S. Food & Drug Administration (FDA) approved Seattle Genetics’ Adcetris and Kadcyla in 2011. Further developments of these drugs have made them non-cleavable and alleviate the chances of it affecting healthy cells.
Participants in the market still employ the use of cell gene expression system to produce these Ig’s. The purity of these antibodies affects the potency of the drug or medicine. Sutro Biopharma, Inc., a US-based pharmaceuticals manufacturer, uses cell-free protein synthesis technology to overcome these limitations. This technology allows the development of different variations of antibodies, allowing the best ADCs to be selected. Other companies are employing the services of contract manufacturing organizations (CMOs) to expedite their production process.
The world antibody production market is anticipated at USD 23 billion by 2025. It was estimated at USD 7.4 billion in 2016. The market is primarily driven by the increasing demand of therapeutic antibodies. Patent expiry of various mAbs drugs has prompted many biopharmaceuticals to develop advanced antibodies.
mAbs segment has generated maximum revenue for the market in 2016. This segment is driven by demand of these drugs in treating cancer and blood disorders. Upstream processing and filtration segments are expected to generate lucrative returns over the forecast period (2014 - 2025). North America will continue to dominate the market over the forecast period due the presence of various biopharmaceutical companies in the region. Prominent market players are Pall Corp., INTEGRA Biosciences AG, Cellab GmbH, and Merck KGaA.
No comments:
Post a Comment